About Phathom Pharmaceuticals, Inc.
https://www.phathompharma.comPhathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
CEO
Steven L. Basta
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 93
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:12.47M
Value:$188.74M
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD
Shares:7.46M
Value:$113.01M
MILLENNIUM MANAGEMENT LLC
Shares:5.08M
Value:$76.93M
Summary
Showing Top 3 of 154
About Phathom Pharmaceuticals, Inc.
https://www.phathompharma.comPhathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $49.5M ▲ | $58.59M ▼ | $-29.97M ▲ | -60.55% ▲ | $-0.41 ▲ | $-13.71M ▲ |
| Q2-2025 | $39.5M ▲ | $94.39M ▼ | $-75.81M ▲ | -191.91% ▲ | $-1.05 ▲ | $-58.12M ▲ |
| Q1-2025 | $28.52M ▼ | $103.66M ▲ | $-94.32M ▼ | -330.71% ▼ | $-1.31 ▼ | $-76.07M ▼ |
| Q4-2024 | $29.66M ▲ | $85.27M ▲ | $-74.45M ▲ | -250.98% ▲ | $-1.05 ▲ | $-55.66M ▲ |
| Q3-2024 | $16.35M | $84.79M | $-85.58M | -523.34% | $-1.32 | $-66.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $135.16M ▼ | $240.29M ▼ | $662.82M ▲ | $-422.53M ▼ |
| Q2-2025 | $149.57M ▼ | $250.22M ▼ | $656.05M ▲ | $-405.83M ▼ |
| Q1-2025 | $212.31M ▼ | $294.21M ▼ | $632.58M ▲ | $-338.38M ▼ |
| Q4-2024 | $297.26M ▼ | $378.47M ▼ | $632.05M ▲ | $-253.58M ▼ |
| Q3-2024 | $334.68M | $387.04M | $574.16M | $-187.11M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-29.97M ▲ | $-14.12M ▲ | $-27K ▲ | $-271K ▼ | $-14.41M ▲ | $-14.12M ▲ |
| Q2-2025 | $-75.81M ▲ | $-62.73M ▲ | $-97K ▼ | $80K ▲ | $-62.75M ▲ | $-62.73M ▲ |
| Q1-2025 | $-94.32M ▼ | $-84.93M ▼ | $-18K ▼ | $0 ▼ | $-84.95M ▼ | $-84.95M ▼ |
| Q4-2024 | $-74.45M ▲ | $-63.46M ▲ | $-5K ▲ | $26.05M ▼ | $-37.41M ▼ | $-63.46M ▲ |
| Q3-2024 | $-85.58M | $-63.57M | $-44K | $122.06M | $58.44M | $-63.49M |
CEO
Steven L. Basta
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 93
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:12.47M
Value:$188.74M
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD
Shares:7.46M
Value:$113.01M
MILLENNIUM MANAGEMENT LLC
Shares:5.08M
Value:$76.93M
Summary
Showing Top 3 of 154